15 Lp(a) and PAD Toolkit: Emerging Diagnosis and Management Antisense Oligonucleotide (ASO) a. Pelacarsen - may lower Lp(a) by about 80% CETP inhibitor a. Obicetrapib - may lower Lp(a) by about 45% Small interfering RNA (siRNA) a. Olpasiran - dose-dependent reduction with ASCVD 32 b. SLN360 – dose-dependent reduction of Lp(a) 33 c. Lepodisiran – dose-dependent, long-duration reductions in serum Lp(a) concentrations 34 Emerging Experimental Therapies for Lp(a)
RkJQdWJsaXNoZXIy MjI2NjI=